Rimacalib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRimacalib
Drug Alias Namerimacalibum利马卡利rimacalibSMP-114SM-114
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcium/Calmodulin dependent protein kinase II inhibitors
TargetsCalcium/Calmodulin dependent protein kinase II
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaPolandNetherlands +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDainippon Sumitomo Pharma Europe Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A